SCM
KROS icon

Soros Capital Management’s Keros Therapeutics KROS Stock Holding History

Soros Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,705
Closed -$200K – 62
2021
Q2 		$200K Buy
+4,705
New +$255K 0.02% 67

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Soros Capital Management's KROS Position: Q3 2021 in Review

Soros Capital Management sold out of Keros Therapeutics (KROS) in Q3 2021, closing a stake of 4,705 shares — an estimated $200K sold.

Soros Capital Management first reported a position in KROS in Q2 2021 and held it in 1 quarter. The position peaked at $200K in Q2 2021. 88 funds tracked by Wall St. Rank hold KROS as of Q3 2021.

  • Soros Capital Management reported no remaining Keros Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Soros Capital Management sold 4,705 Keros Therapeutics shares in Q3 2021, an estimated $200K.
  • Soros Capital Management first reported a position in Keros Therapeutics in Q2 2021 and held it in 1 quarter.
  • Soros Capital Management's Keros Therapeutics position peaked at $200K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2021.

Based on Soros Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.